MKI67 and neoplasm: While tumor growth curves revealed no statistical difference between trastuzumab and the combination therapy (Fig. S4), further analysis of histopathological features revealed decreased tumor cell density and lower expression of the proliferative marker Ki‐67 in the tumors of mice treated with the combination therapy compared with trastuzumab‐treated and control mice (Fig. 4B–D).